NCT06817343Active, not recruitingPhase 1
A Long-term Follow up Study of EXG102-031 in Patients With wAMD (Everest LTFU)
An Open-label, Long-term Follow-Up Study to Evaluate the Safety and Tolerability of Gene Therapy With EXG102-031 in Participants With Neovascular Age-related Macular Degeneration
Source: ClinicalTrials.gov · Last updated 8 Apr 2026
Brief summary (registry, in English)
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage. This leakage affects the vision over time and can lead to severe blurriness or blinding. EXG102-031 was made to block the extra vessel formation which would lead to less leakage affecting the vision. Before EXG102-031 can be tested for its efficacy (if it makes vision better), it must be tested to see if it is safely tolerated to confirm it can continue to be studied in more patients with nAMD. This study is designed to fulfill the long-term safety monitoring of EXG102-031. Participants that enroll in this long-term follow-up study have been treated with EXG102-031 under the main study (EXG102-031-211).
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 30 Jan 2025
- Start date
- 10 Sept 2024
- Primary completion date
- Feb 2029
- Lead sponsor
- Exegenesis Bio
- Diseases
- Macular degeneration
- NCT number
- NCT06817343
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 12
- From 10 Sept 2024 to the primary completion date, Feb 2029
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Who the study is looking for
- Must have been previously enrolled in the parent study (EXG102-031-211) and must have received subretinal EXG102-031 in the parent study;
- Are willing and able to sign the study written informed consent form;
- Must be willing and able to comply with all study procedures.
- There are no exclusion Criteria in this study.
Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Erie Retina Research Coordinator of this site? Confirm its status | Erie | United States | Unknown status |
| Sierra Eye Associates Coordinator of this site? Confirm its status | Reno | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.